DU
KRON

Delphia (USA)’s Kronos Bio KRON Stock Holding History

Delphia (USA)’s Portfolio KRON Stock Details KRON Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-14,256
Closed -$52K – 360
2022
Q2 		$52K Buy
+14,256
New +$64.6K 0.04% 371

Other funds holding KRON

OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VVA
Vida Ventures Advisors Boston, Massachusetts $29.4M AUM 93.58% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return

Delphia (USA)'s KRON Position: Q3 2022 in Review

Delphia (USA) sold out of Kronos Bio (KRON) in Q3 2022, closing a stake of 14,256 shares — an estimated $52K sold.

Delphia (USA) first reported a position in KRON in Q2 2022 and held it in 1 quarter. The position peaked at $52K in Q2 2022. 96 funds tracked by Wall St. Rank hold KRON as of Q3 2022.

  • Delphia (USA) reported no remaining Kronos Bio position as of Q3 2022 after selling out during the quarter.
  • Delphia (USA) sold 14,256 Kronos Bio shares in Q3 2022, an estimated $52K.
  • Delphia (USA) first reported a position in Kronos Bio in Q2 2022 and held it in 1 quarter.
  • Delphia (USA)'s Kronos Bio position peaked at $52K in Q2 2022.
  • 96 funds tracked by Wall St. Rank held Kronos Bio as of Q3 2022.

Based on Delphia (USA)'s 13F filing for Q3 2022, filed 14 Nov 2022.